- Abstract
- Keywords
- Introduction
- Chemistry of BD
- Antineoplastic effects of BD in human malignancies
- Anti-metastatic effects of BD
- Potential anti-inflammatory effects of BD
- Pharmacokinetics, toxicity and metabolism
- Clinical application of BD
- Conclusion and future directions
- Abbreviations
- Declarations
- References
-
Citing Article List
The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management”.No. Publication Date Citing Article 1 2025 Oscar R. Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge I. Castañeda-Sánchez, Elena Aréchaga-Ocampo, Estefanía Valle-Velázquez, Juan C. Cabrera-Angeles, José L. Sánchez-Gloria, Fausto Sánchez-Muñoz, Abraham S. Arellano-Buendia, Laura G. Sánchez-Lozada, Horacio Osorio-Alonso. Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors, Life Sciences. 2025; 372: 123638123638. https://doi.org/10.1016/j.lfs.2025.123638 2 2025 Khushi Dahiya, Mahesh Palkar, Sanjay Sharma. Unlocking the potential of THR-β agonist therapies: resmetirom’s chemistry, biology, and patent insights, Naunyn-Schmiedeberg's Archives of Pharmacology. 2025; https://doi.org/10.1007/s00210-025-03880-y -
